[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07417774":3,"trial-entities:NCT07417774":89,"trial-summary:NCT07417774":92},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":25,"interventions":28,"primary_outcomes":29,"secondary_outcomes":34,"sex":41,"minimum_age":42,"maximum_age":23,"healthy_volunteers":14,"eligibility_criteria":43,"std_ages":48,"locations":51,"central_contacts":85,"overall_officials":86,"references":87,"see_also_links":88},"NCT07417774","RESTORE LB","Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic","ENROLLING_BY_INVITATION","2030-12","2026-02","2026-02-18","2025-12-08","NuvOx LLC","INDUSTRY",false,"The goal of this sub-study of the RESTORE trial is to identify biomarkers associated with tumor hypoxia, identify biomarkers that differentiate pseudoprogression from true progression, and correlate biomarkers with clinical outcomes.","Blood samples for liquid biopsy will be collected at the same time as the scheduled blood draws in the RESTORE study and analyzed by FYR Diagnostics.",[18],"Glioblastoma (GBM)",[20,21],"Glioblastoma","Liquid Biopsy","OBSERVATIONAL",null,[],{"count":26,"type":27},40,"ESTIMATED",[],[30],{"measure":31,"description":32,"timeFrame":33},"Tumor hypoxia biomarkers","Identify differentially expressed tumor hypoxia markers in newly-diagnosed glioblastoma subjects treated with NanO2 versus placebo in the RESTORE study.","until disease progression and up to 5 years",[35,38],{"measure":36,"description":37,"timeFrame":33},"Biomarker expression","To measure differentially expressed biomarkers that distinguish pseudoprogression from true progression",{"measure":39,"description":40,"timeFrame":33},"Relationship between biomarker levels, MGMT methylation status, and survival outcomes","Evaluate whether biomarker levels are associated with MGMT promoter methylation status and how long study participants live without their disease getting worse (Progression-Free Survival) and how long they live overall (Overall Survival). This will help determine whether the biomarkers may predict patient outcomes.","ALL","18 Years",{"inclusion":44,"exclusion":46,"raw_text":47},[45],"Subjects must be enrolled in the RESTORE study (NCT03862430) and provide written informed consent for the RESTORE LB sub-study",[],"Inclusion Criteria:\n\n* Subjects must be enrolled in the RESTORE study (NCT03862430) and provide written informed consent for the RESTORE LB sub-study",[49,50],"ADULT","OLDER_ADULT",[52,61,69,77],{"facility":53,"city":54,"state":55,"zip":56,"country":57,"geoPoint":58},"Center for Neurosciences","Tucson","Arizona","85718","United States",{"lat":59,"lon":60},32.22174,-110.92648,{"facility":62,"city":63,"state":64,"zip":65,"country":57,"geoPoint":66},"Yale Cancer Center","New Haven","Connecticut","06520",{"lat":67,"lon":68},41.30815,-72.92816,{"facility":70,"city":71,"state":72,"zip":73,"country":57,"geoPoint":74},"Saint Luke's Cancer Institute","Kansas City","Missouri","64111",{"lat":75,"lon":76},39.09973,-94.57857,{"facility":78,"city":79,"state":80,"zip":81,"country":57,"geoPoint":82},"Duke University Medical Center","Durham","North Carolina","27710",{"lat":83,"lon":84},35.99403,-78.89862,[],[],[],[],{"nct_id":4,"conditions":90,"biomarkers":91},[20],[],{"nct_id":4,"found":14,"summary":23,"prompt_version":23}]